110 Chapter 5 8 mg/kg group, followed by the fixed dose tocilizumab group, and worst in the low dose tocilizumab and sarilumab group (P <0.0001) (Supplementary Figure 5). Supplementary Figure 2. Multivariable Cox proportional hazards regression analysis, looking at 60-day mortality and correcting for age, sex, immunocompromised status and Charlson Comorbidity index Supplementary Figure 1. Unadjusted Kaplan-Meier survival curve, all patients
RkJQdWJsaXNoZXIy MTk4NDMw